Current Report Filing (8-k)
04 January 2017 - 9:09AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
January 3, 2017
FORTRESS BIOTECH, INC.
(Exact Name of Registrant as Specified in
Charter)
Delaware
|
001-35366
|
20-5157386
|
(State or Other Jurisdiction
of Incorporation)
|
(Commission
File Number)
|
(IRS Employer
Identification No.)
|
2
Gansevoort Street, 9th Floor, New York, New York
|
10014
|
(Address
of Principal Executive Offices)
|
(Zip
Code)
|
Registrant’s Telephone Number, Including
Area Code:
(781) 652-4500
Check the appropriate box below if the Form 8-K filing
is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
|
¨
|
Written communications pursuant to Rule 425 under the Securities Act
(17 CFR 230.425)
|
|
¨
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act
(17 CFR 240.14a-12)
|
|
¨
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the
Exchange Act (17 CFR 240.14d-2(b))
|
|
¨
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the
Exchange Act (17 CFR 240.13e-4(c))
|
|
Item 1.01.
|
Entry into a Material Definitive Agreement.
|
On January 3, 2017, Fortress Biotech, Inc. (the
“Company”) gave notice to NSC BIOTECH VENTURE FUND I LLC (the “Holder”) to extend the maturity date
of the Company’s $10.0 million Promissory Note issued to Holder and dated February 27, 2015, as amended and restated
on July 29, 2015 (the “Note”) by an additional six months such that the new maturity date of the Note is
September 30, 2018. The maturity date of the SubCo Note (as such term is defined in the Note) previously issued by the
Company’s majority-owned subsidiary, Avenue Therapeutics, Inc., to the Holder was also extended to September 30, 2018.
The other terms of the Note remain unchanged, and were reported in the Company’s Current Report on Form 8-K filed with
the U.S. Securities and Exchange Commission on August 4, 2015.
SIGNATURE
Pursuant to the requirements of the Securities
Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned thereunto duly authorized.
|
FORTRESS
BIOTECH, INC.
|
|
|
|
|
Date: January
3, 2017
|
|
|
|
|
/s/
Lindsay A. Rosenwald
|
|
|
Name:
|
Lindsay A.
Rosenwald, M.D.
|
|
|
Title:
|
Chairman
of the Board of Directors,
President and Chief Executive Officer
|
|
Fortress Biotech (NASDAQ:FBIO)
Historical Stock Chart
From Apr 2024 to May 2024
Fortress Biotech (NASDAQ:FBIO)
Historical Stock Chart
From May 2023 to May 2024